Shares of Avadel Pharmaceuticals PLC (NASDAQ:AVDL) reached a new 52-week low on Monday . The stock traded as low as $1.15 and last traded at $1.18, with a volume of 1500 shares trading hands. The stock had previously closed at $1.29.
Several analysts have recently weighed in on AVDL shares. Laidlaw set a $2.00 price objective on shares of Avadel Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, March 18th. Zacks Investment Research upgraded shares of Avadel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. LADENBURG THALM/SH SH lowered shares of Avadel Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, February 8th. Finally, ValuEngine lowered shares of Avadel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 26th. Two analysts have rated the stock with a sell rating and five have issued a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $5.08.
The company has a market cap of $45.89 million, a P/E ratio of -0.62 and a beta of 1.78. The company has a debt-to-equity ratio of 41.63, a quick ratio of 3.13 and a current ratio of 3.25.
Avadel Pharmaceuticals (NASDAQ:AVDL) last announced its quarterly earnings results on Friday, March 15th. The company reported ($0.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.06. The business had revenue of $20.92 million during the quarter. Avadel Pharmaceuticals had a negative net margin of 92.29% and a negative return on equity of 126.79%. Equities analysts forecast that Avadel Pharmaceuticals PLC will post -1.39 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the business. HRT Financial LLC purchased a new position in Avadel Pharmaceuticals during the 4th quarter worth $33,000. Paloma Partners Management Co purchased a new position in Avadel Pharmaceuticals during the 4th quarter worth $59,000. Millennium Management LLC purchased a new position in Avadel Pharmaceuticals during the 4th quarter worth $189,000. Highbridge Capital Management LLC purchased a new position in Avadel Pharmaceuticals during the 4th quarter worth $253,000. Finally, Fosun International Ltd purchased a new position in Avadel Pharmaceuticals during the 4th quarter worth $826,000. 53.43% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was posted by Macon Daily and is the property of of Macon Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://macondaily.com/2019/04/17/avadel-pharmaceuticals-avdl-sets-new-52-week-low-at-1-15.html.
Avadel Pharmaceuticals Company Profile (NASDAQ:AVDL)
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.
Read More: Dollar Cost Averaging
Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.